RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 St

RDHL: RedHill Biopharma Ltd.
2020-07-31 07:00:10
RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections
Beyond Technical Analysis

Declinazione di responsabilità